Massoud Toussi
Medical Director, Real World Evidence Solutions Health Economics and Outcomes Research @Ims Health
Signup · Get unlimited contacts
WORK HISTORY
Medical Director, Real World Evidence Solutions Health Economics and Outcomes Research @Ims Health
Paris, FR
My job consists of bringing medical and methodological expertise to our research teams in Pricing and Market Access, Health Economics and Outcomes Research (HEOR). Our activity is not limited to this and we cover safety studies, too. We accompany our clients in their strategic decision making as early as Phase studies and then through the whole drug life cycle. Our teams bring a state of the art expertise to provide all that pharmaceutical and biotech laboratories need for thier marketing athorisation, pricing and reimbursment dossiers and for increasing their market shares amont competitors. We bring a real and evidence based competitive advantage to our clients.
EDUCATION
Pierre and Marie Curie University
M.Sc., Medical Informatics
Université du Québec à Montréal / UQAM
Executive MBA, International Business, Executive MBA
For Drug Consulting
Certificate, Pharmacovigilance
Univesity of Medical Sciences
M.D., Medicine
Université Panthéon Sorbonne (Paris I)
BA, Cinema
Université Paris 13
Ph.D., Medical Informatics
Université Paris Dauphine
Executive MBA, International Business, Executive MBA
ABOUT MASSOUD TOUSSI
I joined IQVIA in 2011 to build its actual offer in pharmacoepidemiology and drug safety in the context of the then upcoming pharmacovigilance regulation released by the European Medicines Agency (EMA). In this role, I developed the “Epidemiology, Safety and Risk Management” activity of the company from business plan to hiring people and direct involvement in business development, bidding, designing, and conduct of post-authorization safety studies (PASS), comparative effective research (CER), drug utilization studies (DUS), surveys and systematic reviews. Currently, through a network of more than 60 people across the globe, we commercialize and implement robust multi-country studies designed and conducted to comply with the requirements of EMA, FDA and other regulatory agencies, as well as health technology assessment (HTA) bodies. We conduct studies based on both primary data collection, secondary data collection (claims, EMR, registries, etc) and hybrid methods. A highly connected person, I consider myself as a salesman of ideas, solutions and talents, acting in a highly scientific market. I am a member of the real world evidence task force of the International Society of Pharmacoepidemiology (ISPE), and a co-author European Network of Centers for Pharmacoepidemiology and Pharmacovigilance (ENCePP) guide for methodological standards, chair of the real world evidence and artificial intelligence interest group of the International Health Technology Assessment Society (HTAi), and member of the steering committee of transparency initiative of the International Society of Pharmacoeconomics and Outcomes Research (ISPOR). I am also Editor in Chief of the Epidemiology Open Access Journal and a member of the Board of Directors of EU2P, a consortium of 7 European Universities providing Masters and PhD degrees in Pharmacoepidemiology.
This profile is compiled from publicly available professional sources. Unifers is not affiliated with or endorsed by LinkedIn. Request removal of this profile.